Allergy Diagnostics and Therapeutics Market (By Product: Instruments, Consumables, Services; By Drug Class: Nasal Anti-cholinergic, Antihistamines, Corticosteroids, Mast Cell Stabilizers, Leukotriene Inhibitors, Epinephrine, Immunotherapy, Decongestants, Immuno-modulators; By Test: In vivo Test, In vitro Test; By Allergen Type: Food, Inhaled, Drug, Other Allergens; By End-user) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Allergy Diagnostics and Therapeutics Market
5.1. COVID-19 Landscape: Allergy Diagnostics and Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Allergy Diagnostics and Therapeutics Market, By Product
8.1. Allergy Diagnostics and Therapeutics Market, by Product, 2024-2033
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Consumables
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Allergy Diagnostics and Therapeutics Market, By Drug Class
9.1. Allergy Diagnostics and Therapeutics Market, by Drug Class, 2024-2033
9.1.1. Nasal Anti-cholinergic
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Antihistamines
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Corticosteroids
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Mast Cell Stabilizers
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Leukotriene Inhibitors
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Epinephrine
9.1.6.1. Market Revenue and Forecast (2021-2033)
9.1.7. Immunotherapy
9.1.7.1. Market Revenue and Forecast (2021-2033)
9.1.8. Decongestants
9.1.8.1. Market Revenue and Forecast (2021-2033)
9.1.9. Immuno-modulators
9.1.9.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Allergy Diagnostics and Therapeutics Market, By Test
10.1. Allergy Diagnostics and Therapeutics Market, by March, 2024-2033
10.1.1. In vivo Test
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. In vitro Test
10.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Allergy Diagnostics and Therapeutics Market, By By Allergen Type
11.1. Allergy Diagnostics and Therapeutics Market, by By Allergen Type, 2024-2033
11.1.1. Food
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Inhaled
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Drug
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Other Allergens
11.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Allergy Diagnostics and Therapeutics Market, By End-user
12.1. Allergy Diagnostics and Therapeutics Market, by End-user, 2024-2033
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Diagnostics Labs
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. Research & Development Centers
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. Others
12.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Allergy Diagnostics and Therapeutics Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.1.3. Market Revenue and Forecast, by Test(2021-2033)
13.1.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.1.5. Market Revenue and Forecast, by End-user (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Test(2021-2033)
13.1.6.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.1.6.5. Market Revenue and Forecast, by End-user (2021-2033)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.7.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.1.7.3. Market Revenue and Forecast, by Test(2021-2033)
13.1.7.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.1.7.5. Market Revenue and Forecast, by End-user (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.2.3. Market Revenue and Forecast, by Test(2021-2033)
13.2.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.2.5. Market Revenue and Forecast, by End-user (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Test(2021-2033)
13.2.7. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.2.8. Market Revenue and Forecast, by End-user (2021-2033)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Test(2021-2033)
13.2.10. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.2.11. Market Revenue and Forecast, by End-user (2021-2033)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.12.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.2.12.3. Market Revenue and Forecast, by Test(2021-2033)
13.2.12.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.2.13. Market Revenue and Forecast, by End-user (2021-2033)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.14.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.2.14.3. Market Revenue and Forecast, by Test(2021-2033)
13.2.14.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.2.15. Market Revenue and Forecast, by End-user (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.3.3. Market Revenue and Forecast, by Test(2021-2033)
13.3.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.3.5. Market Revenue and Forecast, by End-user (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Test(2021-2033)
13.3.6.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.3.7. Market Revenue and Forecast, by End-user (2021-2033)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Test(2021-2033)
13.3.8.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.3.9. Market Revenue and Forecast, by End-user (2021-2033)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.10.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.3.10.3. Market Revenue and Forecast, by Test(2021-2033)
13.3.10.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.3.10.5. Market Revenue and Forecast, by End-user (2021-2033)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.11.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.3.11.3. Market Revenue and Forecast, by Test(2021-2033)
13.3.11.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.3.11.5. Market Revenue and Forecast, by End-user (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.4.3. Market Revenue and Forecast, by Test(2021-2033)
13.4.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.4.5. Market Revenue and Forecast, by End-user (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Test(2021-2033)
13.4.6.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.4.7. Market Revenue and Forecast, by End-user (2021-2033)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Test(2021-2033)
13.4.8.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.4.9. Market Revenue and Forecast, by End-user (2021-2033)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.10.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.4.10.3. Market Revenue and Forecast, by Test(2021-2033)
13.4.10.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.4.10.5. Market Revenue and Forecast, by End-user (2021-2033)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.11.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.4.11.3. Market Revenue and Forecast, by Test(2021-2033)
13.4.11.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.4.11.5. Market Revenue and Forecast, by End-user (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.5.3. Market Revenue and Forecast, by Test(2021-2033)
13.5.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.5.5. Market Revenue and Forecast, by End-user (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Test(2021-2033)
13.5.6.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.5.7. Market Revenue and Forecast, by End-user (2021-2033)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.8.2. Market Revenue and Forecast, by Drug Class (2021-2033)
13.5.8.3. Market Revenue and Forecast, by Test(2021-2033)
13.5.8.4. Market Revenue and Forecast, by By Allergen Type (2021-2033)
13.5.8.5. Market Revenue and Forecast, by End-user (2021-2033)
Chapter 14. Company Profiles
14.1. R-Biopharm AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. EUROIMMUN Medizinische Labordiagnostika AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. DASIT Group SPA
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. bioMérieux
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Thermo Fisher Scientific, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Stallergenes Greer
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Sun Pharmaceutical Industries Ltd
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Minaris Medical America, Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Siemens Healthcare GmbH
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. AESKU.GROUP GmbH
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client